Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H32N4O4.H2O |
Molecular Weight | 434.5292 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.OC(=O)C[C@H](NC(=O)[C@@H]1CCCN(C1)C(=O)CCC2CCNCC2)C3=CN=CC=C3
InChI
InChIKey=VHTVZWUXMIOMAD-VOMIJIAVSA-N
InChI=1S/C22H32N4O4.H2O/c27-20(6-5-16-7-10-23-11-8-16)26-12-2-4-18(15-26)22(30)25-19(13-21(28)29)17-3-1-9-24-14-17;/h1,3,9,14,16,18-19,23H,2,4-8,10-13,15H2,(H,25,30)(H,28,29);1H2/t18-,19+;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11672755Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17115723 | http://adisinsight.springer.com/drugs/800010575
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11672755
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17115723 | http://adisinsight.springer.com/drugs/800010575
Elarofiban is a novel nonpeptide glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist. It inhibits thrombin-induced platelet aggregation in human gel-filtered platelets and platelet aggregation in human platelet-rich plasma (PRP) in response to collagen, arachidonic acid, ADP, and SFLLRN-NH(2). Elarofiban had adequate oral pharmacokinetics in dogs and excellent oral pharmacodynamics. Elarofiban has been in phase II clinical trials for the treatment of myocardial infarction and thrombosis. However, this research has been discontinued.
Originator
Sources: http://www.google.ch/patents/US6069254
Curator's Comment: the subsidiary of Johnson & Johnson
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17115723
Oral: 3 mg/kg
Intravenous: 0.03 mg/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17115723
Elarofiban inhibited platelet aggregation in human platelet-rich plasma in response to multiple agonists (collagen, ADP, TRAP-6, arachidonic acid; IC50 = 60-160 nM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29750
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034131
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
216231
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
C72753
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
LL-72
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
6Y891C0JEV
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
221005-96-5
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL87728
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
DTXSID70944740
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY | |||
|
C402922
Created by
admin on Fri Dec 15 16:30:26 GMT 2023 , Edited by admin on Fri Dec 15 16:30:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD